AngioDynamics Files 8-K for Regulation FD Disclosure

TL;DR

**AngioDynamics just dropped an 8-K for Regulation FD, leveling the info playing field.**

AI Summary

AngioDynamics, Inc. filed an 8-K on January 11, 2024, primarily to satisfy Regulation FD Disclosure requirements. This filing indicates that the company may have made non-public information public, likely during an investor communication, which is now being formally disclosed. For investors, this matters because it ensures all shareholders have access to the same information simultaneously, preventing unfair trading advantages based on selective disclosure.

Why It Matters

This filing ensures transparency and fair information access for all investors, preventing selective disclosure of material non-public information.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure to comply with Regulation FD, indicating no immediate negative or positive operational impact.

Analyst Insight

A smart investor would note this filing as a routine compliance update, confirming the company's adherence to fair disclosure rules, but it doesn't provide new material information for investment decisions.

Key Numbers

• $0.01 — par value per share (par value of AngioDynamics' Common Stock)

Key Players & Entities

• AngioDynamics, Inc. (company) — the registrant filing the 8-K
• January 11, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for AngioDynamics, Inc.
• 000-50761 (company) — Commission File Number for AngioDynamics, Inc.
• 11-3146460 (company) — IRS Employer Identification No. for AngioDynamics, Inc.
• 14 Plaza Drive, Latham, New York 12110 (company) — principal executive offices address for AngioDynamics, Inc.
• 518-795-1400 (company) — registrant's telephone number
• Common Stock, par value $0.01 per share (dollar_amount) — description of AngioDynamics' registered securities
• ANGO (company) — trading symbol for AngioDynamics' Common Stock
• NASDAQ Global Select Market (company) — exchange where AngioDynamics' Common Stock is registered

FAQ

Key Financial Figures

• $0.01 — registered Common Stock, par value $0.01 per share ANGO NASDAQ Global Select

Filing Documents

• ef20018682_8k.htm (8-K) — 28KB
• ef20018682_ex99-1.htm (EX-99.1) — 29KB
• image00006.jpg (GRAPHIC) — 39KB
• image00007.jpg (GRAPHIC) — 64KB
• image00008.jpg (GRAPHIC) — 44KB
• image00009.jpg (GRAPHIC) — 47KB
• image00010.jpg (GRAPHIC) — 67KB
• image00011.jpg (GRAPHIC) — 66KB
• image00012.jpg (GRAPHIC) — 68KB
• image00013.jpg (GRAPHIC) — 69KB
• image00014.jpg (GRAPHIC) — 67KB
• image00015.jpg (GRAPHIC) — 57KB
• image00016.jpg (GRAPHIC) — 72KB
• image00017.jpg (GRAPHIC) — 47KB
• image00018.jpg (GRAPHIC) — 39KB
• image00019.jpg (GRAPHIC) — 58KB
• 0001140361-24-001849.txt ( ) — 1308KB
• ango-20240111.xsd (EX-101.SCH) — 4KB
• ango-20240111_lab.xml (EX-101.LAB) — 22KB
• ango-20240111_pre.xml (EX-101.PRE) — 16KB
• ef20018682_8k_htm.xml (XML) — 4KB

01 – Regulation FD Disclosure

Item 7.01 – Regulation FD Disclosure. On January 11, 2024, James Clemmer, President and Chief Executive Officer of AngioDynamics, Inc. ("AngioDynamics"), will present at the J.P. Morgan 42nd Annual Healthcare Conference. The presentation slides are furnished herewith as Exhibit 99.1. The presentation slides furnished pursuant to Item 7.01 of this Form 8-K (including Exhibit 99.1) shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities under that Section. Furthermore, the presentation slides shall not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act.

Forward-Looking Statements

Forward-Looking Statements This document and its attachments contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All of management for future operations, as well as statements that include the words such as "expects," "reaffirms," "intends," "anticipates," "plans," "believes," "seeks," "estimates," "projects", "optimistic," or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics' expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics' technology or assertions that AngioDynamics' technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of produ

01 – Financial Statements and Exhibits

Item 9.01 – Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 99.1 Presentation slides for the J.P. Morgan 42nd Annual Healthcare Conference, dated January 11, 2024 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ANGIODYNAMICS, INC. (Registrant) Date: January 11, 2024 By: /s/ Stephen A. Trowbridge Name: Stephen A. Trowbridge Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR